Literature DB >> 34232070

Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.

Sai Priya Anand1,2, Shilei Ding1, William D Tolbert3, Jérémie Prévost1,4, Jonathan Richard1,4, Hwi Min Gil5,6, Gabrielle Gendron-Lepage1, Wing-Fai Cheung7, Haifeng Wang7, Rebecca Pastora7, Hirak Saxena8, Warren Wakarchuk8, Halima Medjahed1, Bruce D Wines9,10,11, Mark Hogarth9,10,11, George M Shaw12, Malcom A Martin13, Dennis R Burton14,15, Lars Hangartner14, David T Evans5,6, Marzena Pazgier3, Doug Cossar7, Michael D McLean7, Andrés Finzi1,2,4.   

Abstract

The activity of broadly neutralizing antibodies (bNAbs) targeting HIV-1 depends on pleiotropic functions, including viral neutralization and the elimination of HIV-1-infected cells. Several in vivo studies have suggested that passive administration of bNAbs represents a valuable strategy for the prevention or treatment of HIV-1. In addition, different strategies are currently being tested to scale up the production of bNAbs to obtain the large quantities of antibodies required for clinical trials. Production of antibodies in plants permits low-cost and large-scale production of valuable therapeutics; furthermore, pertinent to this work, it also includes an advanced glycoengineering platform. In this study, we used Nicotiana benthamiana to produce different Fc-glycovariants of a potent bNAb, PGT121, with near-homogeneous profiles and evaluated their antiviral activities. Structural analyses identified a close similarity in overall structure and glycosylation patterns of Fc regions for these plant-derived Abs and mammalian cell-derived Abs. When tested for Fc-effector activities, afucosylated PGT121 showed significantly enhanced FcγRIIIa interaction and antibody dependent cellular cytotoxicity (ADCC) against primary HIV-1-infected cells, both in vitro and ex vivo. However, the overall galactosylation profiles of plant PGT121 did not affect ADCC activities against infected primary CD4+ T cells. Our results suggest that the abrogation of the Fc N-linked glycan fucosylation of PGT121 is a worthwhile strategy to boost its Fc-effector functionality. IMPORTANCE PGT121 is a highly potent bNAb and its antiviral activities for HIV-1 prevention and therapy are currently being evaluated in clinical trials. The importance of its Fc-effector functions in clearing HIV-1-infected cells is also under investigation. Our results highlight enhanced Fc-effector activities of afucosylated PGT121 MAbs that could be important in a therapeutic context to accelerate infected cell clearance and slow disease progression. Future studies to evaluate the potential of plant-produced afucosylated PGT121 in controlling HIV-1 replication in vivo are warranted.

Entities:  

Keywords:  ADCC; Env glycoproteins; Envelope glycoproteins; FcγRIIIa; HIV-1; Nicotiana benthamiana; PGT121; broadly neutralizing antibodies; fucose; galactose; glycosylation; neutralizing antibodies; plant antibodies

Mesh:

Substances:

Year:  2021        PMID: 34232070      PMCID: PMC8387047          DOI: 10.1128/JVI.00796-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  88 in total

1.  Dimeric Fcγ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of Fcγ Receptor Antibodies Induced by the RV144 Vaccine Trial.

Authors:  Milla R McLean; Vijaya Madhavi; Bruce D Wines; P Mark Hogarth; Amy W Chung; Stephen J Kent
Journal:  J Immunol       Date:  2017-06-14       Impact factor: 5.422

2.  A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection.

Authors:  Richard T Davey; Lori Dodd; Michael A Proschan; James Neaton; Jacquie Neuhaus Nordwall; Joseph S Koopmeiners; John Beigel; John Tierney; H Clifford Lane; Anthony S Fauci; Moses B F Massaquoi; Foday Sahr; Denis Malvy
Journal:  N Engl J Med       Date:  2016-10-13       Impact factor: 91.245

3.  Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants.

Authors:  Julian K-C Ma; Jürgen Drossard; David Lewis; Friedrich Altmann; Julia Boyle; Paul Christou; Tom Cole; Philip Dale; Craig J van Dolleweerd; Valerie Isitt; Dietmar Katinger; Martin Lobedan; Hubert Mertens; Mathew J Paul; Thomas Rademacher; Markus Sack; Penelope A C Hundleby; Gabriela Stiegler; Eva Stoger; Richard M Twyman; Brigitta Vcelar; Rainer Fischer
Journal:  Plant Biotechnol J       Date:  2015-07-03       Impact factor: 9.803

4.  Blocking HIV-1 replication: are Fc-Fcγ receptor interactions required?

Authors:  Donald Forthal; Andrés Finzi
Journal:  J Clin Invest       Date:  2018-11-26       Impact factor: 14.808

5.  Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.

Authors:  M H Tao; S L Morrison
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

6.  A Small-Molecule CD4-Mimetic Compound Protects Bone Marrow-Liver-Thymus Humanized Mice From HIV-1 Infection.

Authors:  Amy M Princiotto; Vladimir D Vrbanac; Bruno Melillo; Jongwoo Park; Andrew M Tager; Amos B Smith; Joseph Sodroski; Navid Madani
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

7.  The pFF plasmids: cassettes utilising CaMV sequences for expression of foreign genes in plants.

Authors:  M C Timmermans; P Maliga; J Vieira; J Messing
Journal:  J Biotechnol       Date:  1990-06       Impact factor: 3.307

8.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.

Authors:  Marina Caskey; Till Schoofs; Henning Gruell; Allison Settler; Theodora Karagounis; Edward F Kreider; Ben Murrell; Nico Pfeifer; Lilian Nogueira; Thiago Y Oliveira; Gerald H Learn; Yehuda Z Cohen; Clara Lehmann; Daniel Gillor; Irina Shimeliovich; Cecilia Unson-O'Brien; Daniela Weiland; Alexander Robles; Tim Kümmerle; Christoph Wyen; Rebeka Levin; Maggi Witmer-Pack; Kemal Eren; Caroline Ignacio; Szilard Kiss; Anthony P West; Hugo Mouquet; Barry S Zingman; Roy M Gulick; Tibor Keler; Pamela J Bjorkman; Michael S Seaman; Beatrice H Hahn; Gerd Fätkenheuer; Sarah J Schlesinger; Michel C Nussenzweig; Florian Klein
Journal:  Nat Med       Date:  2017-01-16       Impact factor: 53.440

9.  Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria.

Authors:  Michael-Paul Robinson; Na Ke; Julie Lobstein; Cristen Peterson; Alana Szkodny; Thomas J Mansell; Corinna Tuckey; Paul D Riggs; Paul A Colussi; Christopher J Noren; Christopher H Taron; Matthew P DeLisa; Mehmet Berkmen
Journal:  Nat Commun       Date:  2015-08-27       Impact factor: 14.919

10.  Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.

Authors:  Leopold Kong; Jeong Hyun Lee; Katie J Doores; Charles D Murin; Jean-Philippe Julien; Ryan McBride; Yan Liu; Andre Marozsan; Albert Cupo; Per-Johan Klasse; Simon Hoffenberg; Michael Caulfield; C Richter King; Yuanzi Hua; Khoa M Le; Reza Khayat; Marc C Deller; Thomas Clayton; Henry Tien; Ten Feizi; Rogier W Sanders; James C Paulson; John P Moore; Robyn L Stanfield; Dennis R Burton; Andrew B Ward; Ian A Wilson
Journal:  Nat Struct Mol Biol       Date:  2013-05-26       Impact factor: 15.369

View more
  2 in total

1.  A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells.

Authors:  Guillaume Beaudoin-Bussières; Jonathan Richard; Jérémie Prévost; Guillaume Goyette; Andrés Finzi
Journal:  STAR Protoc       Date:  2021-09-13

Review 2.  Natural Killer Cells in Antibody Independent and Antibody Dependent HIV Control.

Authors:  Nicole F Bernard; Sanket Kant; Zahra Kiani; Cécile Tremblay; Franck P Dupuy
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.